Výsledky vyhledávání - "Lennart Kühl"

Akademický článek

eIg-based bispecific T-cell engagers targeting EGFR: Format matters

Autor: Lennart Kühl, Annelie K. Schäfer, Sebastian Kraft, Nadine Aschmoneit, Roland E. Kontermann, Oliver Seifert

Publikováno v: mAbs, Vol 15, Iss 1 (2023)

ABSTRACTBispecific antibodies are molecules with versatile modes of action and applications for therapy. They are commonly developed as T-cell engagers (TCE), which simultaneously target an antigen expressed by tumor cells and CD3 expressed by T-cell

Externí odkaz: https://doaj.org/article/dedeb020f41f452187e36cd60d89c9b7

Zobrazit plný text záznamu

Akademický článek

The eIg technology to generate Ig-like bispecific antibodies

Autor: Lennart Kühl, Nadine Aschmoneit, Roland E. Kontermann, Oliver Seifert

Publikováno v: mAbs, Vol 14, Iss 1 (2022)

Bispecific antibodies have emerged as therapeutic molecules with a multitude of modes of action and applications. Here, we present a novel approach to solve the light-chain problem for the generation of bispecific Ig-like antibodies using the second

Externí odkaz: https://doaj.org/article/cd764e6089e841b09a9a9bf18df4cbbd

Zobrazit plný text záznamu

Akademický článek

Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)

Autor: Nadine Aschmoneit, Katharina Kocher, Martin Siegemund, Martina S. Lutz, Lennart Kühl, Oliver Seifert, Roland E. Kontermann

Publikováno v: OncoImmunology, Vol 11, Iss 1 (2022)

Targeting costimulatory receptors of the tumor necrosis factor superfamily (TNFSF) to activate T-cells and promote anti-tumor T-cell function have emerged as a promising strategy in cancer immunotherapy. Previous studies have shown that combining two

Externí odkaz: https://doaj.org/article/576ebae1bf8c4fda872afd57290e2490

Zobrazit plný text záznamu

Akademický článek

A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells

Autor: Nadine Aschmoneit, Sophia Steinlein, Lennart Kühl, Oliver Seifert, Roland E. Kontermann

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)

Abstract HER3 is a member of the EGF receptor family and elevated expression is associated with cancer progression and therapy resistance. HER3-specific T-cell engagers might be a suitable treatment option to circumvent the limited efficacy observed

Externí odkaz: https://doaj.org/article/d989d218664f4b1999818ee6967f204d

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3

Autor: Alexander Rau, Katharina Kocher, Mirjam Rommel, Lennart Kühl, Maximilian Albrecht, Hannes Gotthard, Nadine Aschmoneit, Bettina Noll, Monilola A. Olayioye, Roland E. Kontermann, Oliver Seifert

Publikováno v: mAbs, Vol 13, Iss 1 (2021)

Dual targeting of surface receptors with bispecific antibodies is attracting increasing interest in cancer therapy. Here, we present a novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting human epidermal growth factors 2 and 3 (HER2

Externí odkaz: https://doaj.org/article/8f87b491057b4795a191a891a563a0e7

Zobrazit plný text záznamu

Data from Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer

Autor: Monilola A. Olayioye, Roland E. Kontermann, Matthias Schwab, Markus Morkel, Christine Sers, Marc-H. Dahlke, Thomas E. Mürdter, Svetlana Kalmykova, Thomas Sell, Lennart Kühl, Nicole Janssen, Alexander Rau

Current treatment options for patients with advanced colorectal cancers include anti-EGFR/HER1 therapy with the blocking antibody cetuximab. Although a subset of patients with KRAS WT disease initially respond to the treatment, resistance develops in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac07161b78811188c6e65f85ea0017af
https://doi.org/10.1158/1535-7163.c.6543369

Zobrazit plný text záznamu